From Blockbusters to Biomarkers: Rethinking Commercialization for the Precision Era and the Importance of Diagnostic Testing

It’s clear that traditional blockbuster models don't work well for precision medicine. Traditional models are built for broad patient groups. They can be costly and don’t fit the needs of therapies designed for specific biomarkers. Diagnostic testing helps identify the right patients for the right treatments.

Innovation Has Outpaced Commercialization.

Despite rapid advances in precision medicine, commercialization strategies have struggled to keep pace. The assumption that diagnostic testing will follow a drug launch has proven wrong. Testing can lag, and patients are missed if pharma, labs, diagnostics, and physicians don't collaborate early. Traditional models rely on large sales teams and broad campaigns. They often fail to reach physicians when treatment decisions are being made. Traditional models rely on large sales teams and broad campaigns. They often miss physicians at crucial moments when treatment decisions are made. The financial burden is immense and untenable for precision therapies.

As a result, we’re seeing promising treatments being deprioritized, abandoned, or returned to licensors. This is not due to clinical shortcomings, but because the commercial model cannot support their targeted nature.

The Case for Change.

This growing disconnect calls for a different approach, one as precise as the therapies it supports. Enter: Targeted Commercialization. Pioneered by Diaceutics to help new treatments reach the right patients at the right time.

What Makes Targeted Commercialization Different?

• Strategic Partnership, Not Just a Service. Targeted Commercialization starts with close collaboration and a clear understanding of each treatment.
• Powered by Real-World Data. This model uses real-time data to show what is happening across testing and treatment. Including where diagnostic testing gaps remain.
• Persona-Driven Engagement. We engage labs and physicians through digital and personal channels. Providing them with timely, relevant messages.
• Cost-Efficient, Flexible Models. Flexible pricing links costs to results, helping biopharma companies manage costs and reduce risk.

The Bottom Line

We believe commercialization should be as precise as the therapies it supports. And with Targeted Commercialization supported by diagnostic testing, we’re proving that it can be.